Cantor Fitzgerald Estimates Organogenesis FY2025 Earnings

Organogenesis Holdings Inc. (NASDAQ:ORGO) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Organogenesis in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn expects that the company will post earnings of ($0.08) per share for the year. The consensus estimate for Organogenesis’ current full-year earnings is ($0.07) per share.

Organogenesis Stock Down 0.8 %

Shares of NASDAQ:ORGO opened at $3.50 on Thursday. The business’s 50-day simple moving average is $3.50 and its 200 day simple moving average is $3.10. Organogenesis has a one year low of $2.16 and a one year high of $4.57. The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21.

Organogenesis (NASDAQ:ORGO) last posted its earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.11. The firm had revenue of $115.18 million for the quarter, compared to analyst estimates of $109.59 million. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. During the same quarter in the prior year, the company earned $0.02 EPS.

Insider Buying and Selling at Organogenesis

In other news, CEO Gary S. Gillheeney sold 41,052 shares of the stock in a transaction on Monday, December 9th. The stock was sold at an average price of $3.52, for a total value of $144,503.04. Following the completion of the transaction, the chief executive officer now owns 3,359,726 shares of the company’s stock, valued at approximately $11,826,235.52. This represents a 1.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders have sold 278,116 shares of company stock worth $991,190 in the last ninety days. 36.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Assenagon Asset Management S.A. raised its stake in shares of Organogenesis by 54.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 2,950,849 shares of the company’s stock valued at $9,443,000 after acquiring an additional 1,035,120 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of Organogenesis by 76.9% during the 2nd quarter. AQR Capital Management LLC now owns 2,268,760 shares of the company’s stock worth $6,353,000 after acquiring an additional 986,132 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Organogenesis by 19.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,036,743 shares of the company’s stock valued at $5,702,000 after purchasing an additional 333,123 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Organogenesis by 107.8% during the third quarter. JPMorgan Chase & Co. now owns 205,943 shares of the company’s stock valued at $589,000 after acquiring an additional 106,823 shares during the period. Finally, Cubist Systematic Strategies LLC boosted its holdings in shares of Organogenesis by 1,350.3% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 94,705 shares of the company’s stock worth $265,000 after acquiring an additional 88,175 shares in the last quarter. Institutional investors own 49.57% of the company’s stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.